The global chemotherapy market size was valued at USD 28.73 billion in 2025 and is projected to grow from USD 31.56 billion in 2026 to USD 67.01 billion by 2034 at a CAGR of 9.87% during the forecast period 2026-2034. North America dominated the chemotherapy market with a market share of 41.2% in 2025.
One or more chemotherapeutic agents, such as anti-cancer medications, are used in chemotherapy, a cancer treatment. By destroying the dividing cells, the treatment primarily stops the division and growth of cancer cells. Additionally, it is used to treat a variety of cancers, including ovarian cancer, breast cancer, leukemia, myeloma, sarcoma, and lymphoma. Chemotherapy medications can be administered intravenously or specifically target specific cancer sites.
Download a Free Sample To learn more about this report,
The chemotherapy market is evolving from the use of traditional standalone chemotherapy toward combination treatment approaches that improve patient outcomes while reducing severe side effects. One of the strongest trends is the increasing use of chemotherapy alongside immunotherapy and targeted therapies. In 2025, results presented at the American Society of Clinical Oncology (ASCO) showed that combining chemotherapy with the immunotherapy drug atezolizumab reduced the risk of disease recurrence and death by about 50% in patients with stage III deficient mismatch repair (dMMR) colon cancer compared with chemotherapy alone.
Another important trend is the growing use of personalized chemotherapy, where genomic and biomarker testing helps doctors select the most effective treatment regimen for each patient. This approach minimizes unnecessary chemotherapy exposure while improving treatment response. In addition, hospitals are increasingly adopting supportive care medicines, advanced infusion technologies, and remote patient monitoring to better manage chemotherapy-related toxicities.
The chemotherapy market is primarily driven by the rising global burden of cancer, which continues to increase the demand for effective treatment options. Growing adoption of combination therapies, where chemotherapy is used alongside immunotherapy and targeted therapies, is improving treatment outcomes and expanding its clinical use. Advances in personalized medicine and biomarker testing are helping physicians choose more suitable chemotherapy regimens for individual patients. Expanding healthcare infrastructure, improved access to oncology services in emerging economies, increasing regulatory approvals for cancer drugs, and continuous investments in cancer research are also supporting market growth. Additionally, the growing elderly population, which is more vulnerable to cancer, continues to contribute to the increasing demand for chemotherapy treatments.
The chemotherapy market faces several restraints that limit its growth. Severe treatment-related side effects often reduce patient compliance and affect quality of life. The high cost of advanced chemotherapy regimens and supportive care creates financial challenges for patients and healthcare systems. The increasing adoption of targeted therapies and immunotherapies in certain cancers is reducing reliance on conventional chemotherapy. Drug resistance in some cancer types can also lower treatment effectiveness. In addition, lengthy regulatory approval processes, occasional shortages of chemotherapy drugs, limited access to specialized oncology care in developing regions, and supply chain disruptions continue to challenge the steady growth of the chemotherapy market.
The chemotherapy market has strong growth opportunities due to the increasing use of combination therapies with immunotherapy and targeted drugs, creating an estimated positive impact of 17.4%. Rising demand for personalized cancer treatment supported by genomic and biomarker testing is expected to contribute around 15.1% to market growth. Expansion of cancer treatment centers and oncology infrastructure in emerging economies is projected to generate a 13.3% positive impact. The growing adoption of oral chemotherapy drugs for convenient outpatient treatment is expected to add approximately 11.2% to market expansion. In addition, continuous investment in oncology research, AI-assisted drug discovery, and the development of next-generation chemotherapy formulations is estimated to create a 9.6% positive impact over the coming years.
The chemotherapy market continues to face several challenges despite ongoing innovation. The increasing preference for targeted therapies and immunotherapies over conventional chemotherapy is estimated to have a negative impact of 16.5% on market growth. Rising treatment costs and affordability issues are expected to reduce market expansion by approximately 14.2%. Drug resistance and reduced effectiveness of chemotherapy in certain cancers create a 12.1% negative impact. Frequent shortages of essential chemotherapy drugs and supply chain disruptions are estimated to affect the market by around 10.4%. Additionally, strict regulatory requirements, lengthy clinical development timelines, and concerns about treatment-related toxicity are projected to have a combined negative impact of 8.8% on overall market growth.
Request Customizationto receive a tailored report.
Alkylating Agents
Alkylating agents held the largest share of the chemotherapy drugs market, accounting for 27.6% of the total market in 2025. The segment reached a market value of USD 7.93 billion and is expected to grow at a CAGR of 6.83% during the forecast period. These drugs continue to play a major role in cancer treatment because they are widely used against several types of solid tumors and blood cancers. Their long history of clinical use, broad therapeutic applications, and inclusion in standard chemotherapy regimens support their leading market position. Continuous demand from hospitals and oncology centers also contributes to stable growth.
Antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and other chemotherapy drugs continue to support the overall market through their unique treatment roles. Antimetabolites remain widely prescribed for blood-related cancers, while anti-tumor antibiotics are commonly included in combination treatment plans. Topoisomerase inhibitors are gaining attention because of their effectiveness against difficult-to-treat cancers. Mitotic inhibitors continue to be important for breast and lung cancer therapies, and the remaining drug categories help address specific clinical needs, giving healthcare providers more treatment options across different cancer types.
Lung Cancer
Lung cancer is projected to register the highest growth among indications, expanding at a CAGR of 7.74% during the forecast period. The segment accounted for 18.9% of the global market and reached a value of USD 5.43 billion in 2025. Rising smoking-related diseases, increasing exposure to environmental pollution, and growing awareness of early diagnosis are supporting demand for chemotherapy treatments. Although targeted therapies are expanding, chemotherapy continues to remain a key treatment option, particularly for advanced-stage patients and combination treatment approaches.
Leukemia, lymphoma, breast cancer, ovarian cancer, myeloma, sarcoma, and other cancer indications continue to create strong demand for chemotherapy drugs worldwide. Blood cancers require established chemotherapy regimens that remain part of standard clinical practice. Breast cancer treatment continues to rely on chemotherapy in several stages of care despite advances in targeted medicine. Ovarian cancer, myeloma, and sarcoma also contribute steadily as healthcare providers adopt personalized treatment strategies. The remaining cancer indications collectively expand market opportunities by increasing the need for diverse chemotherapy options across healthcare systems.
Intravenous
Intravenous administration dominated the market with a 65.5% share in 2025. The segment generated USD 18.82 billion in market value and is projected to grow at a CAGR of 6.79%. Intravenous chemotherapy remains the preferred route because it delivers medicines directly into the bloodstream, allowing faster action and precise dosage control. It is widely used for patients receiving intensive treatment in hospitals and specialized oncology centers. The ability to administer complex drug combinations under medical supervision further strengthens the dominance of this segment across cancer treatment settings.
The oral route is becoming increasingly important as healthcare providers focus on improving patient convenience and treatment flexibility. Oral chemotherapy allows many patients to continue treatment at home, reducing the need for frequent hospital visits. Better patient compliance, ongoing development of new oral formulations, and improved monitoring technologies are encouraging wider adoption. Growing interest in patient-centered care and advancements in pharmaceutical research are expected to support the continued expansion of oral chemotherapy across different cancer indications.
Research Institutes
Research institutes are expected to record the highest growth, advancing at a CAGR of 7.89% during the forecast period. The segment accounted for 15.4% of the market and reached USD 4.42 billion in 2025. Increasing investments in oncology research, rising clinical trial activity, and the development of innovative chemotherapy combinations are driving this growth. Academic organizations and research centers are working closely with pharmaceutical companies to evaluate new treatment approaches, making research institutes an important contributor to future market expansion.
Hospitals remain the primary centers for chemotherapy administration because they provide comprehensive oncology services, experienced healthcare professionals, and advanced treatment infrastructure. Most patients receive chemotherapy in hospital settings due to the need for monitoring, supportive care, and multidisciplinary treatment planning. Other end users, including specialty clinics and ambulatory care facilities, are also expanding their role by offering convenient treatment options for selected patients. Together, these healthcare settings improve treatment accessibility while supporting the overall growth of the chemotherapy market.
Speak to an Analystto discuss market opportunities.
North America is the largest regional market for chemotherapy, accounting for 41.2% of the global market. The region is valued at USD 11.84 billion and is projected to grow at a CAGR of 6.82%. Market growth is supported by the high prevalence of cancer, strong healthcare infrastructure, widespread availability of advanced oncology treatments, increasing adoption of combination therapies, and ongoing investments in cancer research and clinical trials.
The United States is part of the North American chemotherapy market. The region accounts for 41.2% of the global market, with a total market value of USD 11.84 billion and a CAGR of 6.82%. These figures represent the overall North American region. The U.S. market benefits from advanced cancer treatment facilities, high adoption of innovative chemotherapy regimens, significant research activities, and favorable reimbursement systems.
Canada is part of the North American chemotherapy market. The region holds 41.2% of the global market, valued at USD 11.84 billion, and is expected to grow at a CAGR of 6.82%. These figures represent the overall North American region. Market growth in Canada is supported by expanding access to cancer care, increasing healthcare investments, and the growing adoption of modern chemotherapy and supportive care services.
Asia Pacific accounts for 21.8% of the global chemotherapy market, with a regional market value of USD 6.26 billion. The region is expected to record the fastest growth at a CAGR of 8.96%. Growth is driven by rising cancer incidence, expanding healthcare infrastructure, improving access to oncology treatments, increasing healthcare spending, and a growing patient population across developing economies.
Japan is part of the Asia Pacific chemotherapy market. The region represents 21.8% of the global market, with a value of USD 6.26 billion and a CAGR of 8.96%. These figures represent the overall Asia Pacific region. Japan's market growth is supported by an aging population, advanced healthcare services, strong cancer screening programs, and continuous adoption of innovative cancer therapies.
China is part of the Asia Pacific chemotherapy market. The region holds 21.8% of the global market, valued at USD 6.26 billion, and is projected to grow at a CAGR of 8.96%. These figures represent the overall Asia Pacific region. Growth is driven by increasing cancer cases, expanding oncology infrastructure, rising healthcare expenditure, and greater availability of cancer treatment services.
Europe holds 27.4% of the global chemotherapy market, with a market value of USD 7.87 billion, and is expected to grow at a CAGR of 6.51%. Market growth is supported by well-established healthcare systems, increasing demand for personalized cancer treatment, strong pharmaceutical research, and growing investments in oncology care.
Germany is part of the European chemotherapy market. The region accounts for 27.4% of the global market, valued at USD 7.87 billion, with a CAGR of 6.51%. These figures represent the overall European region. Germany benefits from advanced oncology centers, strong clinical research capabilities, and high adoption of modern chemotherapy treatment protocols.
The United Kingdom is part of the European chemotherapy market. The region represents 27.4% of the global market, with a value of USD 7.87 billion and a CAGR of 6.51%. These figures represent the overall European region. Market growth is supported by continuous improvements in cancer care services, government healthcare programs, and increasing use of combination cancer therapies.
Latin America accounts for 5.6% of the global chemotherapy market, with a regional value of USD 1.61 billion, and is projected to grow at a CAGR of 7.48%. The market is expanding due to improving healthcare access, increasing awareness of cancer diagnosis and treatment, and growing investments in oncology services.
Brazil is part of the Latin American chemotherapy market. The region holds 5.6% of the global market, valued at USD 1.61 billion, and is expected to grow at a CAGR of 7.48%. These figures represent the overall Latin American region. Growth is supported by expanding cancer treatment facilities, increasing healthcare spending, and improved access to oncology services.
The Middle East & Africa accounts for 4.0% of the global chemotherapy market, with a market value of USD 1.15 billion, and is expected to grow at a CAGR of 6.94%. Market growth is driven by improving healthcare infrastructure, increasing cancer awareness, expanding access to oncology treatments, and government initiatives to strengthen healthcare services.
The UAE is part of the Middle East & Africa chemotherapy market. The region accounts for 4.0% of the global market, with a value of USD 1.15 billion and a CAGR of 6.94%. These figures represent the overall Middle East & Africa region. The UAE market is supported by ongoing investments in advanced healthcare infrastructure, increasing availability of specialized oncology centers, and rising demand for high-quality cancer treatment services.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com